Navigation Links
FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads
Date:6/20/2011

SILVER SPRING, Md., June 20, 2011 /PRNewswire-USNewswire/ -- Findings from three studies conducted by the U.S. Food and Drug Administration confirm that the way information is conveyed and displayed in printed drug advertising affects consumer understanding of prescription medications.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The studies, designed by experts in FDA's Division of Drug, Marketing, Advertising and Communications (DDMAC) in the Center for Drug Evaluation and Research, examined ways to improve understanding of how consumers use the "brief summary" section of printed prescription drug ads.

The online edition of the journal "Medical Decision Making" published findings from the third study today.

The Federal Food, Drug, and Cosmetic Act specifies that print advertisements for prescription drugs and biological products are required to provide a true statement of information "in brief summary" about the advertised product's "side effects, contraindications, and effectiveness."  

"Some of the current approaches to fulfilling the brief summary requirement, while adequate from a regulatory perspective, are not optimal in communicating this important information to consumers," said Thomas Abrams, director of DDMAC. "FDA's research and policy development seeks to improve the presentation of this information so it is easier for consumers to read and understand."

Print ads for prescription drugs are often two (or more) pages long. The first page of the prescription drug ad may feature a picture, information about what the product is intended to be used for, and important information about the product's risks. The second page summarizes all the product's risks and may be presented as densely-packed text information.

In the first study, a serious risk was added to the first and second page of the ad.  In the second study, additional information about side effects was included on the second page.  The third study tested four different brief summary formats:

Traditional (block text paragraphs), Question and Answer (with headings framed in the form of questions), Highlights (based on the highlights section of the physician labeling), and Prescription Drug Facts Box (resembling the current Over the Counter Drug Facts label).

Key findings of the studies include:

  • Adding a serious risk did not hinder people's understanding of the risk information.
  • Including additional information about how often side effects occur and how long they may last did not hinder people's understanding of the risk information.
  • Participants who viewed the Drug Facts format were better able to recall risks than those who saw the traditional format.

FDA researchers Kathryn Aikin, Ph.D., Amie O'Donoghue, Ph.D., and Helen Sullivan, Ph.D., M.P.H., and Jack Swasy, Ph.D., from American University designed and led the three experimental studies.

A copy of "Randomized Trial of Risk Information Formats for Brief Summary in Direct-to-Consumer (DTC) Print Advertisements for Prescription Drugs" will be available in the September/October 2011 issue of "Medical Decision Making."

For more information:

Randomized Trial of Risk Information Formats for Brief Summary in Direct-to-Consumer (DTC) Print Advertisements for Prescription Drugs

Background on Prescription Drug Advertising

Division of Drug Marketing, Advertising and Communication (DDMAC) Research  

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AAHC Examines Nations Clinical Trials Infrastructure
2. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
3. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
4. Turning the Page in HIV Prevention Research: An AIDS Vaccine is Possible — AVAC Examines The Way Forward
5. New Report by BioTrends Examines the Treatment of Renal Anemia in China
6. New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law
7. New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
8. UL White Paper Examines Key Implications of Growing Home Healthcare Industry
9. FDLIs Food and Drug Policy Forum Examines European GMO Rules
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):